Real-World Studies
First-Line Platinum-Based Chemotherapy in Octogenarians With Metastatic Urothelial Carcinoma
Minato et alCancer Diagnosis & Prognosis
A retrospective study evaluated the efficacy and safety of first-line platinum-based chemotherapy (PBC) in 30 octogenarian patients (median age 83 years; range 80–92) with metastatic urothelial carcinoma (mUC) treated between 2005 and 2022. Primary tumor locations included the bladder in 17 patients and the upper urinary tract in 13 patients. All patients had a baseline performance status of 0 (n=15) or 1 (n=15), and 60% (n=18) had lymph node-only metastatic disease. Administered regimens included gemcitabine plus platinum in 24 patients (15 receiving carboplatin) and methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) in 6 patients, with patients receiving a median of 3 treatment cycles.
First-line PBC demonstrated antitumor activity, achieving an objective response rate of 40.0% and a disease control rate of 76.7%. Survival analysis showed a median progression-free survival of 5.2 months and a median overall survival of 11.3 months. However, treatment burden was high: grade ≥3 treatment-related adverse events were reported in 76.7% of patients (n=23), consisting primarily of hematologic toxicities related to myelosuppression. Dose reductions were required in 70.0% of patients (n=21), and 46.7% (n=14) discontinued therapy due to toxicity (n=7) or patient preference (n=7). While first-line PBC remains an active treatment option for select octogenarians with mUC, the high rate of myelosuppression underscores the necessity of careful patient selection and proactive toxicity management.
Key Takeaways
- First-line platinum-based chemotherapy yielded an objective response rate of 40% and a disease control rate of 76.7% in patients aged 80 years or older with metastatic urothelial carcinoma, achieving a median progression-free survival of 5.2 months and a median overall survival of 11.3 months.
- Grade ≥3 treatment-related adverse events occurred in 76.7% of octogenarians—predominantly myelosuppression—requiring dose reductions in 70% of patients and leading to treatment discontinuation in 46.7%.
Read the original sourceCancer Diagnosis & Prognosis
